FMT from Aged Mice Shifts Protein Expression, Impairs Cognition in Young Mice
FMT study shows that in mice, age-associated shifts of the microbiota alter expression of hippocampal proteins and impair spatial learning and memory
Related Articles
Gene Therapy for Inherited Deafness Approaches a Threshold
Research successes are driving gene therapy for inherited deafness to the clinic, but commercialization efforts are needed to sustain momentum.
StockWatch: Wall Street’s Leaders and Laggards of 2024
GEN presents data compiled by Morningstar’s Morningstar Direct asset management platform for StockWatch of the top five performing biotech stocks of 2024, and the five…
3D-Printed Tumors Replicate Biopsies of Cancer Patients
Carcinotech can generate hundreds of printed tumors from one biopsy, intensifying cancer drug screening and personalized medicine testing.
Five Deaf Children Have Hearing Restored by AAV-Based Gene Therapy
Clinical trial results suggest that five out of six children treated with a gene therapy for hearing loss demonstrated hearing recovery.
Caloric Restriction vs. Intermittent Fasting: Large Mouse Study Offers Insights and Raises Questions
Findings implied more generally that the effects of dietary restriction on health and lifespan may be partially non-overlapping.
Culprit behind Psoriasis Revealed
If two copies of the mutated gene (known as IKBKB) are present, patients with psoriasis may go on to develop psoriatic arthritis.
Switching Gene Therapy On and Off with a Pill
Besides offering a gene expression switch, MeiraGTx attends to vector optimization, manufacturing, and pipeline expansion.
Optimizing TFF for mRNA Filtration
As scientists look to model every aspect of mRNA processing, publicly available data on tangential flow filtration (TFF) is noticeably absent.
DNA-Based Vaccine Production Provides Best Shot at Profitability
Despite being positive about DNA-based vaccine production in general, the study did identify areas in need of better manufacturing technologies.
Akamis Bio Raises $60 Million for Cancer Gene Therapy, Signs Licensing Deal with Xuanzhu Biopharma
The company is launching a Phase Ib study that will test its first gene therapy in patients with locally advanced rectal cancer.